Abstract

T-cell receptors can recognize foreign peptides bound to major histocompatibility complex (MHC) class-I proteins, and thus trigger the adaptive immune response. Therefore, identifying peptides that can bind to MHC class-I molecules plays a vital role in the design of peptide vaccines. Many computational methods, for example, the state-of-the-art allele-specific method , have been developed to predict the binding affinities between peptides and MHC molecules. In this manuscript, we develop two allele-specific Convolutional Neural Network-based methods named and to tackle the binding prediction problem. Specifically, we formulate the problem as to optimize the rankings of peptide-MHC bindings via ranking-based learning objectives. Such optimization is more robust and tolerant to the measurement inaccuracy of binding affinities, and therefore enables more accurate prioritization of binding peptides. In addition, we develop a new position encoding method in and to better identify the most important amino acids for the binding events. We conduct a comprehensive set of experiments using the latest Immune Epitope Database (IEDB) datasets. Our experimental results demonstrate that our models significantly outperform the state-of-the-art methods including with an average percentage improvement of 6.70% on AUC and 17.10% on ROC5 across 128 alleles.

Highlights

  • Immunotherapy, an important treatment of cancers, treats the disease by boosting patients’ immune systems to kill cancer cells (Mellman et al, 2011; Couzin-Frankel, 2013; Esfahani et al, 2020; Waldman et al, 2020)

  • Kim et al (2009) derived a novel amino acid similarity matrix named Peptide:major histocompatibility complex (MHC) Binding Energy Covariance (PMBEC) matrix and incorporated it into the Stabilized Matrix Method (SMM) approach to improve the performance of SMM

  • The values in the table are percentage improvement compared with the baseline MHCflurry with MS

Read more

Summary

Introduction

Immunotherapy, an important treatment of cancers, treats the disease by boosting patients’ immune systems to kill cancer cells (Mellman et al, 2011; Couzin-Frankel, 2013; Esfahani et al, 2020; Waldman et al, 2020). To trigger patients’ adaptive immune responses, Cytotoxic T cells, known as CD8+ T-cells, have to recognize peptides presented on the cancer cell surface (Valitutti et al, 1995; Blum et al, 2013). These peptides are fragments derived from self-proteins or pathogens by proteasomal proteolysis within the cell. To design successful peptide vaccines, it is critical to identify and study peptides that can bind with MHC class-I molecules

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.